ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

GENE Genetic Technologies Ltd

2.27
-0.05 (-2.16%)
Última actualización: 12:13:04
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Genetic Technologies Ltd GENE NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.05 -2.16% 2.27 12:13:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.40 2.25 2.40 2.32
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202414:00GLOBEGenetic Technologies Announces Closing of US$2 Million..
18/4/202411:17GLOBEGenetic Technologies Announces $2 Million Registered Direct..
17/4/202407:00GLOBENew Precision Oncology Tests to Drive Personalised Therapies..
16/4/202407:00GLOBEGeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year..
11/4/202407:00GLOBEGTG to pilot GeneType in Breast Screen centers across the..
08/4/202407:00GLOBEEVENT - Empowering Women Through Knowledge; Humanise Health..
02/4/202407:05GLOBEGenetic Technologies’ Digital Strategy Ignites Significant..
26/3/202407:00GLOBEGTG Global Collaborations and Innovation Update
25/3/202407:00GLOBEGENE to develop Worlds Most Advanced Comprehensive Risk Test..
26/2/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/2/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/2/202413:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202407:00GLOBELaunching our most comprehensive test and expanding into new..
09/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202407:00GLOBEGenetic Technologies Regains Compliance with Nasdaq Minimum..
04/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
28/12/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/12/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202316:00EDGAR2Form F-3 - Registration statement by foreign private issuers
14/12/202307:00GLOBEGeneType's Groundbreaking Saliva Test Transforms Early..
12/12/202307:00GLOBEGenetic Technologies Limited Announces Ordinary Share..
30/10/202307:00GLOBEGene Business Update: Private Hospital Partnership; Expanded..
18/10/202307:30GLOBEGeneType Predicting Risk of Pancreatic Cancer: Major..
27/9/202308:00GLOBEGTG Signs Precision Medicine Pilot with Australia’s Largest..
12/9/202307:00GLOBEBreakthrough: GeneType for Pancreatic Cancer, Melanoma, and..
11/9/202307:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202307:30GLOBEGENE Positioned at the Forefront of Multi-cancer Clinical..
11/9/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202309:00GLOBEGenetic Technologies Limited and 60 Degrees Pharmaceuticals..
30/8/202307:45GLOBEAnnual Results – Momentum Building on our Commercial Plans
09/8/202307:00GLOBEGenetic Technologies Limited Announces Updated Investor..
28/7/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/7/202307:00GLOBEQuarterly Activities Update: Encouraging Growth for geneType..
21/7/202307:00GLOBEGenetic Technologies Receives Nasdaq Notification Regarding..
23/5/202307:00GLOBEGeneType featured on U.S. National TV to raise Breast Cancer..

Su Consulta Reciente

Delayed Upgrade Clock